Metastatic Ttf 1 Negative Lung Adenocarcinoma clinical trials

Explore recruiting metastatic ttf 1 negative lung adenocarcinoma clinical trials.

Also recruiting in Europe

Metastatic Ttf 1 Negative Lung Adenocarcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

ANTELOPE – Atezolizumab/Carboplatin/nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in metastatic TTF-1 negative lung adenocarcinoma

Germany

Therapeutic use (Phase IV) EU CTIS Study details

Metastatic Ttf 1 Negative Lung Adenocarcinoma trials by city

Metastatic Ttf 1 Negative Lung Adenocarcinoma in Toronto Metastatic Ttf 1 Negative Lung Adenocarcinoma in Vancouver Metastatic Ttf 1 Negative Lung Adenocarcinoma in Montreal Metastatic Ttf 1 Negative Lung Adenocarcinoma in Calgary Metastatic Ttf 1 Negative Lung Adenocarcinoma in Edmonton Metastatic Ttf 1 Negative Lung Adenocarcinoma in Ottawa Metastatic Ttf 1 Negative Lung Adenocarcinoma in Winnipeg Metastatic Ttf 1 Negative Lung Adenocarcinoma in Quebec City Metastatic Ttf 1 Negative Lung Adenocarcinoma in Hamilton Metastatic Ttf 1 Negative Lung Adenocarcinoma in Kitchener Metastatic Ttf 1 Negative Lung Adenocarcinoma in London Metastatic Ttf 1 Negative Lung Adenocarcinoma in Halifax Metastatic Ttf 1 Negative Lung Adenocarcinoma in New York Metastatic Ttf 1 Negative Lung Adenocarcinoma in Los Angeles Metastatic Ttf 1 Negative Lung Adenocarcinoma in Chicago Metastatic Ttf 1 Negative Lung Adenocarcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease